CHU de Caen, Department of Infectious Diseases, Avenue de la Côte de Nacre, Caen F-14000, France.
CHU de Caen, Department of Infectious Diseases, Avenue de la Côte de Nacre, Caen F-14000, France.
Vaccine. 2021 Jul 22;39(32):4410-4413. doi: 10.1016/j.vaccine.2021.06.054. Epub 2021 Jun 23.
Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population.
An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers.
Subjects with prior COVID-19 disease history (n = 61) had higher systemic reactions than subjects without any previous history (n = 1987) (45.9% vs 29.7%, p = 0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p = 0.045, 19.7% vs 9.3% p = 0.01, 6.5% vs 0.9% p = 0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p = 0.03).
Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance.
评估 BNT162b2 mRNA Covid-19 疫苗安全性的研究排除了既往有 COVID-19 感染史的受试者。我们研究的目的是关注该人群对这种疫苗的耐受性。
在两个接种中心，在第一剂疫苗接种后 21 至 28 天，对受试者进行了一项与疫苗安全性和耐受性相关的匿名自我报告调查。
有既往 COVID-19 病史的受试者（n=61）的全身性反应发生率高于无任何既往病史的受试者（n=1987）（45.9% vs 29.7%，p=0.01）。乏力、头痛和发热在 COVID-19 阳性组比阴性组更常见（25.6% vs 15.2%，p=0.045；19.7% vs 9.3%，p=0.01；6.5% vs 0.9%，p=0.003）。COVID-19 阳性组的严重程度更高（p=0.03）。
我们的研究证实，既往有 SARS-CoV-2 疾病史的患者发生副作用的风险较高，但总体耐受性良好。
